Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Jessica M. Clement

Hematology Oncology | Hematology | Oncology
85 Seymour Street, Hartford Hospital Cancer Center, 
Hartford, CT 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in WT1-Related Wilms Tumor Syndromes
85 Seymour Street, Hartford Hospital Cancer Center, 
Hartford, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jessica Clement is a Hematologist Oncology specialist and a Hematologist in Hartford, Connecticut. Dr. Clement is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CT
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

85 Seymour Street, Hartford Hospital Cancer Center, Hartford, CT 06106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Phase 1 Multicenter, Open-Label, Dose Escalation Study and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Enrollment Status: Completed
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: STP705
Study Phase: Phase 1
View 3 Less Clinical Trials

20 Total Publications

Municipal Pathways in Response to COVID-19: A Strategic Management Perspective on Local Public Administration Resilience.
Municipal Pathways in Response to COVID-19: A Strategic Management Perspective on Local Public Administration Resilience.
Journal: Administration & society
Published: January 06, 2023
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeffrey M. Kamradt
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeffrey M. Kamradt
Hematology Oncology | Oncology | Hematology

Hartford Hospital

80 Seymour St, 
Hartford, CT 
 (0.1 miles away)
860-545-7500
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Kamradt is a Hematologist Oncology specialist and an Oncologist in Hartford, Connecticut. Dr. Kamradt is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Clear Cell Sarcoma, and WT1-Related Wilms Tumor Syndromes.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Krishna S. Gunturu
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Krishna S. Gunturu
Hematology Oncology | Hematology | Oncology

The Hospital Of Central Connecticut At New Britain General And Bradley

183 N Mountain Rd, 
New Britain, CT 
 (9.2 miles away)
860-224-5011
Languages Spoken:
English
See accepted insurances

Krishna Gunturu is a Hematologist Oncology specialist and a Hematologist in New Britain, Connecticut. Dr. Gunturu is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), ALK-Positive Non-Small Cell Lung Cancer, Squamous Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and Liver Embolization.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Trevor J. Bayliss
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Trevor J. Bayliss
Hematology Oncology | Hematology | Oncology

Berkshire Faculty Services Inc

165 Tor Ct, 
Pittsfield, MA 
 (57.5 miles away)
413-447-2701
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Trevor Bayliss is a Hematologist Oncology specialist and a Hematologist in Pittsfield, Massachusetts. Dr. Bayliss is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Paget Disease of the Breast, and Colorectal Cancer. Dr. Bayliss is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Clement's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 41 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile